Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12198992 | 0.91 | RARB (0.43) | RARBRARARARGMAPTSKP2 | |
| SCHEMBL12198994 | 0.87 | RARB (0.48) | RARBRARARARGSKP2S1PR1 | |
| SCHEMBL3439549 | 0.86 | RARB (0.37) | RARBAKR1C2AKR1C1CNR2RARA | |
| SCHEMBL3439545 | 0.85 | RARB (0.43) | RARBAKR1C2AKR1C1CNR2RARA | |
| SCHEMBL12198996 | 0.82 | RARB (0.53) | RARBRARARARGGPR3 | |
| SCHEMBL3439544 | 0.81 | RARB (0.41) | RARBAKR1C2AKR1C1RARARARG | |
| SCHEMBL12622909 | 0.80 | RARB (0.52) | RARBRARARARGMAPT | |
| SCHEMBL3439527 | 0.79 | RARB (0.32) | RARBAKR1C2AKR1C1CNR2S1PR1 | |
| SCHEMBL3439561 | 0.79 | RARB (0.32) | RARBS1PR1S1PR3 | |
| SCHEMBL13002284 | 0.79 | RARB (0.40) | RARBAKR1C2AKR1C1RARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8974694-B2 | Liquid-crystal composition | JNC CORPORATION (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8974694-B2 | Liquid-crystal composition | JNC CORPORATION (JP) | 2015-03-10 | — | — | US | disclosed |
| US-20130188107-A1 | LIQUID-CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130188107-A1 | LIQUID-CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2013-07-25 | — | — | US | disclosed |
| US-8409673-B2 | Chlorobenzene derivative, optically isotropic liquid crystal medium, and optical device | JNC CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8409673-B2 | Chlorobenzene derivative, optically isotropic liquid crystal medium, and optical device | JNC CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-26 | — | — | US | disclosed |
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | CRYAB, CYBA, CCNB1 | RARB 153/4885AKR1C2 1926/4885AKR1C1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.